Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis
Cancers · 05.06.2025 · 17 (11) · 1895
DOI: 10.3390/cancers17111895 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.06.2025. Verfasst von Fernando M Runzer-Colmenares und 10 weiteren Autor:innen. Beteiligte Einrichtung: CHANGE Research Working Group, Carrera de Medicina Humana, Universidad Científica del Sur, Lima 15067, Peru. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grupo de Estudios Clínicos Oncológicos del Perú, AstraZeneca.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases globally and most patients receive their diagnosis at advanced or metastatic disease stages. The use of tyrosine kinase inhibitors (TKIs) such as erlotinib (first-generation) and osimertinib (third-generation) to treat NSCLC is possible because of activating mutations in the epidermal growth factor receptor (EGFR). Although osimertinib has shown better results in recent trials, direct and updated comparisons with erlotinib, especially in combination regimens, are still limited. Background/Objectives: This study aimed to compare the efficacy and safety of osimertinib versus erlotinib, both as monotherapies and in combination, in treatment-naïve patients with advanced or metastatic EGFR-mutated NSCLC.
Methods
A systematic review and network meta-analysis were conducted following PRISMA-NMA guidelines and registered in PROSPERO (CRD42025649761). PubMed, EMBASE, and Scopus were searched up to February 2025 for randomized controlled trials (RCTs) that compared erlotinib- or osimertinib-based regimens in previously untreated EGFR-mutated advanced NSCLC. Outcomes included overall survival (OS), progression-free survival (PFS), and grade ≥ 3 adverse events. A frequentist random-effects model was used, and treatments were ranked using p-scores.
Results
Eleven RCTs (2341 patients) were included. Osimertinib, alone or with chemotherapy, resulted in significantly longer OS compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09–2.31). All osimertinib and erlotinib regimens outperformed chemotherapy for PFS, but no statistically significant differences were observed between osimertinib and erlotinib. Severe adverse events were comparable, though osimertinib ranked highest for safety. The combination of osimertinib with chemotherapy achieved the highest p-scores for both OS and PFS.
Conclusions
Osimertinib is associated with superior overall survival and comparable safety versus erlotinib-based strategies in first-line treatment of advanced EGFR-mutated NSCLC. These findings reinforce osimertinib as the preferred first-line option in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CHANGE Research Working Group, Carrera de Medicina Humana, Universidad Científica del Sur, Lima 15067, Peru.
- Departamento de Oncología Médica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15023, Peru.
- Departamento de Medicina Oncológica, Oncosalud-AUNA, Lima 15036, Peru.
- Facultad de Medicina Humana, Universidad Ricardo Palma, Lima 15039, Peru.
- Departamento de Medicina Oncológica, Hospital Nacional PNP "Luis N. Saenz", Lima 15048, Peru.
- Departamento de Oncología Médica, Instituto Regional de Enfermedades Neoplásicas "Dr. Luis Pinillos Ganoza", Trujillo 13007, Peru.
ORCID-Profile: Fernando M Runzer-Colmenares, Luis Puma-Villanueva, Carlos Diaz-Arocutipa
Förderung
- Grupo de Estudios Clínicos Oncológicos del Perú
- AstraZeneca
Zitieren
APA
Runzer-Colmenares, F. M., Ruiz, R., Maco, L., Maldonado, M., Puma-Villanueva, L., Galvez-Nino, M., Aliaga, C., Benites-Zapata, V. A., Diaz-Arocutipa, C., Mas, L., & Urrunaga-Pastor, D. (2025). Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis. Cancers, 17(11), 1895. https://doi.org/10.3390/cancers17111895
Vancouver
Runzer-Colmenares FM, Ruiz R, Maco L, Maldonado M, Puma-Villanueva L, Galvez-Nino M, et al. Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis. Cancers. 2025;17(11):1895. doi:10.3390/cancers17111895
BibTeX
@article{RunzerColmenares2025,
author = {Runzer-Colmenares, Fernando M and Ruiz, Rossana and Maco, Lorenzo and Maldonado, Mike and Puma-Villanueva, Luis and Galvez-Nino, Marco and Aliaga, Carlos and Benites-Zapata, Vicente A and Diaz-Arocutipa, Carlos and Mas, Luis and Urrunaga-Pastor, Diego},
title = {Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis},
journal = {Cancers},
year = {2025},
volume = {17},
number = {11},
pages = {1895},
doi = {10.3390/cancers17111895}
}
EUVIMED